HC Wainwright & Co. Reiterates Buy on Sophia Genetics, Maintains $14 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Sophia Genetics (NASDAQ:SOPH) with a Buy and maintains $14 price target.
Stocks · News reference
Sophia Genetics Q2 EPS $(0.30) Misses $(0.20) Estimate, Sales $23.310M Beat $21.729M Estimate
Sophia Genetics (NASDAQ:SOPH) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate of $(0.20) by 50 percent. This is a 9.09 percent increase over losses of $(0.33) per share from
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
SOPHiA GENETICS, Myriad Genetics Collaborate To Advance New Prostate Cancer-specific Genomic Instability Score Technology
AI Poised to Reshape Blood Cancer Therapeutics as Investment Surges Past $2 Billion Across Leading Biotech and Pharma Players
Artificial intelligence is transforming blood cancer drug discovery and development, with over $2 billion in investment from major biotech and pharma companies. AI is reducing clinical trial timelines by up to 50%, improving patient selection, and enabling next-generation therapies like CAR-T and antibody-drug conjugates. North America leads with 40% of global market share, while Asia-Pacific emerges as a significant growth region.
HC Wainwright & Co. Maintains Buy on Sophia Genetics, Raises Price Target to $14
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Sophia Genetics (NASDAQ:SOPH) with a Buy and raises the price target from $12 to $14.